Log in to your Inderes Free account to see all free content on this page.
Bavarian Nordic
192.45
DKK
-0.31 %
BAVA
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
51 following
-0.31%
-10.86%
-22.09%
+11.11%
+8.45%
+25.91%
-37.09%
+50.36%
+34.93%
www.bavarian-nordic.com/investor.aspx
Bavarian Nordic is a biochemistry company. Today, the company specializes in the development, manufacture, and distribution of vaccines against infectious diseases in connection with cancer treatment. In addition, vaccines against other serious diseases such as Ebola and cervical cancer are also being developed. The largest operations are located in Europe and in the U.S. Bavarian Nordic was founded in 1994 and is headquartered in Kvistgaard, Denmark.
Revenue
7.06B
EBIT %
21.28 %
P/E
10.02
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
BAVA
Daily low / high price
189.05 / 193.45
DKK
Market cap
15.17B DKK
Turnover
66.61M DKK
Volume
347K
Latest videos
Financial calendar
Annual report
05.03.2025
General meeting
09.04.2025
Interim report
09.05.2025
Interim report
22.08.2025
Interim report
14.11.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
ATP Group | 10.1 % | 10.1 % |
Invesco | 5.0 % | 5.0 % |
ShowingAll content types
First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic’s Mpox Vaccine
Bavarian Nordic Upgrades its Financial Guidance for 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio